ALK and lung cancer: Yoda Yoda S S Lin Lin JJ JJ Lawrence Lawrence MS MS Burke Burke BJ BJ Friboulet Friboulet L L Langenbucher Langenbucher A A Sequential ALK inhibitors can select for lorlatinib-resistant compound ALK mutations in ALK-positive lung cancer Sequential ALK inhibitors can select for lorlatinib-resistant compound ALK mutations in ALK-positive lung cancer Cancer Discov Cancer Discov 2018 2018 8 8 6 6 714 714 729 729 10.1158/2159-8290.CD-17-1256 10.1158/2159-8290.CD-17-1256 29650534 29650534